Étude de l’effet neuro-protecteur de polyphénols issus de la Pomme-Grenade ainsi que de leurs dérivés métaboliques
Nowadays, a myriad of beneficial effects is attributed to dietary polyphenols. Most of these claims are based on in vitro studies, some in vivo studies, and almost never on clinical trials. It is increasingly realized that the interest of polyphenols does not only lie in their antioxidant power but also in their ability to target multiple molecular pathways such as inflammation. In addition, many studies are beginning to take into account the bioavailability of polyphenols in the body and their interaction with the gut microbiota. That's why in addition to two polyphenols from Pomegranate, we looked at two of their metabolic derivatives. Almost no study has examined the effect of these molecules in the context of neurodegenerative diseases. To do this, we tested punicalagin, ellagic acid, urolithin A and urolithin B on C. elegans models of ALS and Huntington's disease that had motor phenotypes, neurodegeneration and inflammation. Furthermore, we used a mouse model that underwent an axotomy of the optic nerve to confirm the neuroprotective power of urolithin A. Our results showed that these compounds in different proportions were able to reduce the neuronal toxicity of proteins. related to ALS and HD and thus decrease the levels of paralysis and neuro-degeneration of our C. elegans models. In parallel, we observed that this neuroprotection was done through a reduction of the inflammation and for urolithin A an improvement of the morphology of mitochondria via mitophagy. Lastly, we found that urolithin A was able to promote neuronal survival in mice as a result of optic nerve injury. To conclude, this study by its in vivo approach to multiple neuro-degenerative diseases reinforces existing evidence of the beneficial effect of pomegranate consumption and encourages the pharmacological use of urolithin A.
Neuro-degenerative diseases Pomegranate Polyphenols Metabolic derivatives Neuroprotection